Revelation Biosciences Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.00 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.80Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $3.2M Enterprise Value −$10.9M Shares Outstanding 3.9M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Revelation Biosciences is a clinical-stage biopharmaceutical company focused on developing its lead candidate, Gemini (a proprietary formulation of PHAD®, a TLR4 agonist), for indications such as acute kidney injury (AKI) and chronic kidney disease (CKD). While the company has achieved critical regulatory alignment with the FDA on a single adaptive Phase 2/3 study for Gemini in AKI, it remains a pre-commercial entity with zero revenue, recurring operating losses, and a limited cash runway extending only into Q1 2027. Given the high clinical development risks, potential for further dilutive capital raises, and historical reliance on reverse stock splits to maintain Nasdaq compliance, a Hold recommendation is warranted until pivotal trial initiation and further funding are secured. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$16.00 Mean target$19.25 High · most bullish analyst$22.50 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.0020% The initiation of the Phase 2/3 Gemini AKI study is delayed past Q4 2026 due to operational or manufacturing bottlenecks. The company is forced to raise capital under highly dilutive terms at a depressed valuation, further eroding shareholder value. Additionally, failure to maintain the Nasdaq minimum bid price leads to delisting pressures or highly disruptive reverse stock splits. Base CaseCentral scenario $16.0055% The company proceeds with setting up the infrastructure for the Phase 2/3 Gemini AKI study, targeting a Q4 2026 start. Cash burn remains steady at approximately $3.0M to $3.5M per quarter, requiring the company to raise additional capital before early 2027. The stock remains volatile and highly sensitive to clinical and regulatory updates, with potential reverse stock splits executed to maintain Nasdaq listing compliance. Bull CaseUpside scenario $22.5025% The FDA aligns with a single adaptive Phase 2/3 study of ~300 patients for Gemini in AKI, which could significantly shorten the development timeline and reduce costs. If the trial initiates successfully in Q4 2026 and delivers positive topline data, it could pave the way for a rapid NDA submission. Securing a non-dilutive partnership or strategic collaboration would extend the cash runway and validate the platform's commercial potential. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |